Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
DOI:
https://doi.org/10.1590/S1807-59322011001200022Keywords:
Ductus Arteriosus, Preterm Newborn, Prophilaxis, Indometacin, NSAIDsAbstract
Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.Downloads
Download data is not yet available.
Downloads
Published
2011-01-01
Issue
Section
Reviews
How to Cite
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? . (2011). Clinics, 66(12), 2141-2149. https://doi.org/10.1590/S1807-59322011001200022